Skip to main content

Master of Public Health

Clarifying the causal contrast: An empirical example applying the prevalent new user study design

AUTHORS

Young JC , Webster-Clark M , Shmuel S , Garry EM , Mavros P , Stürmer T , Girman CJ , . Pharmacoepidemiology and drug safety. ; 33(4). e5790

ABSTRACT

PURPOSE: The prevalent new user design extends the active comparator new user design to include patients switching to a treatment of interest from a comparator. We examined the impact of adding “switchers” to incident new users on the estimated hazard ratio (HR) of hospitalized heart failure.

METHODS: Using MarketScan claims data (2000-2014), we estimated HRs of hospitalized heart failure between patients initiating GLP-1 receptor agonists (GLP-1 RA) and sulfonylureas (SU). We considered three estimands: (1) the effect of incident new use; (2) the effect of switching; and (3) the effect of incident new use or switching, combining the two population. We used time-conditional propensity scores (TCPS) and time-stratified standardized morbidity ratio (SMR) weighting to adjust for confounding.

RESULTS: We identified 76 179 GLP-1 RA new users, of which 12% were direct switchers (within 30 days) from SU. Among incident new users, GLP-1 RA was protective against heart failure (adjHR = 0.74 [0.69, 0.80]). Among switchers, GLP-1 RA was not protective (adjHR = 0.99 [0.83, 1.18]). Results in the combined population were largely driven by the incident new users, with GLP-1 RA having a protective effect (adjHR = 0.77 [0.72, 0.83]). Results using TCPS were consistent with those estimated using SMR weighting.

CONCLUSIONS: When analyses were conducted only among incident new users, GLP-1 RA had a protective effect. However, among switchers from SU to GLP-1 RA, the effect estimates substantially shifted toward the null. Combining patients with varying treatment histories can result in poor confounding control and camouflage important heterogeneity.

Tags: